{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:30:38Z","timestamp":1792524638301,"version":"4.5.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["Z01-BC-006150"],"award-info":[{"award-number":["Z01-BC-006150"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008999","name":"Japanese Society of Clinical Pharmacology and Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"HHS | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1ZIATR000047-05"],"award-info":[{"award-number":["1ZIATR000047-05"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Current treatment options for metastatic adrenocortical carcinoma (ACC) have limited efficacy, despite the common use of mitotane and cytotoxic agents. This study aimed to identify novel therapeutic options for ACC. An extensive drug screen was conducted to identify compounds with potential activity against ACC cell lines. We further investigated the mechanism of action of the identified compound, TAK-243, its synergistic effects with current ACC therapeutics, and its efficacy in ACC models including patient-derived organoids and mouse xenografts. TAK-243, a clinical ubiquitin-activating enzyme (UAE) inhibitor, showed potent activity in ACC cell lines. TAK-243 inhibited protein ubiquitination in ACC cells, leading to the accumulation of free ubiquitin, activation of the unfolded protein response, and induction of apoptosis. TAK-243 was found to be effluxed out of cells by MDR1, a drug efflux pump, and did not require Schlafen 11 (SLFN11) expression for its activity. Combination of TAK-243 with current ACC therapies (e.g., mitotane, etoposide, cisplatin) produced synergistic or additive effects. In addition, TAK-243 was highly synergistic with BCL2 inhibitors (Navitoclax and Venetoclax) in preclinical ACC models including patient-derived organoids. The tumor suppressive effects of TAK-243 and its synergistic effects with Venetoclax were further confirmed in a mouse xenograft model. These findings provide preclinical evidence to support the initiation of a clinical trial of TAK-243 in patients with advanced-stage ACC. TAK-243 is a promising potential treatment option for ACC, either as monotherapy or in combination with existing therapies or BCL2 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ACC is a rare endocrine cancer with poor prognosis and limited therapeutic options. We report that TAK-243 is active alone and in combination with currently used therapies and with BCL2 and mTOR inhibitors in ACC preclinical models. Our results suggest implementation of TAK-243 in clinical trials for patients with advanced and metastatic ACC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0085","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T12:26:20Z","timestamp":1709814380000},"page":"834-848","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-0282","authenticated-orcid":true,"given":"Yasuhiro","family":"Arakawa","sequence":"first","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-1355","authenticated-orcid":true,"given":"Ukhyun","family":"Jo","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-8259","authenticated-orcid":true,"given":"Suresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-4104","authenticated-orcid":true,"given":"Nai-Yun","family":"Sun","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7116-508X","authenticated-orcid":true,"given":"Fathi","family":"Elloumi","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-3115","authenticated-orcid":true,"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-5468","authenticated-orcid":true,"given":"Nitin","family":"Roper","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5691-9575","authenticated-orcid":true,"given":"Diana Grace","family":"Varghese","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-4954","authenticated-orcid":true,"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4656","authenticated-orcid":true,"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-9521","authenticated-orcid":true,"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6546","authenticated-orcid":true,"given":"David O.","family":"Holland","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4800-9922","authenticated-orcid":true,"given":"Erin","family":"Beck","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-1326","authenticated-orcid":true,"given":"Zina","family":"Itkin","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6554-5772","authenticated-orcid":true,"given":"Crystal","family":"McKnight","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-2766","authenticated-orcid":true,"given":"Kelli M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-7988","authenticated-orcid":true,"given":"Jameson","family":"Travers","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-6132","authenticated-orcid":true,"given":"Carleen","family":"Klumpp-Thomas","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":true,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"2National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-1434","authenticated-orcid":true,"given":"Chuong D.","family":"Hoang","sequence":"additional","affiliation":[{"name":"3Thoracic Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-0557","authenticated-orcid":true,"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"4Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4030","authenticated-orcid":true,"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3108-0758","authenticated-orcid":true,"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2024031914013579500_bib1","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024031914013579500_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"2024031914013579500_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.seminoncol.2010.10.011","article-title":"Practical considerations in the evaluation and management of adrenocortical cancer","volume":"37","author":"Balasubramaniam","year":"2010","journal-title":"Semin Oncol"},{"key":"2024031914013579500_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2024031914013579500_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1530\/ERC-17-0447","article-title":"Development of new preclinical models to advance adrenocortical carcinoma research","volume":"25","author":"Kiseljak-Vassiliades","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2024031914013579500_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12020-022-03112-w","article-title":"An update on adrenocortical cell lines of human origin","volume":"77","author":"Sigala","year":"2022","journal-title":"Endocrine"},{"key":"2024031914013579500_bib7","doi-asserted-by":"crossref","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","article-title":"CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics","volume":"49","author":"Luna","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2024031914013579500_bib8","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"key":"2024031914013579500_bib9","first-page":"13","article-title":"Understanding mitotane mode of action","volume":"68","author":"Waszut","year":"2017","journal-title":"J Physiol Pharmacol"},{"key":"2024031914013579500_bib10","doi-asserted-by":"crossref","first-page":"E2271","DOI":"10.1073\/pnas.1318262111","article-title":"Activation of the endoplasmic reticulum unfolded protein response by lipid disequilibrium without disturbed proteostasis in vivo","volume":"111","author":"Hou","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024031914013579500_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12576-013-0281-8","article-title":"ABCG1 deficiency promotes endothelial apoptosis by endoplasmic reticulum stress-dependent pathway","volume":"63","author":"Xue","year":"2013","journal-title":"J Physiol Sci"},{"key":"2024031914013579500_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12672-016-0273-2","article-title":"Drug synergism of proteasome inhibitors and mitotane by complementary activation of ER stress in adrenocortical carcinoma cells","volume":"7","author":"Kroiss","year":"2016","journal-title":"Horm Cancer"},{"key":"2024031914013579500_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"2024031914013579500_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2024031914013579500_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2024031914013579500_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1677\/erc.1.01130","article-title":"Adrenocortical cancer: pathophysiology and clinical management","volume":"14","author":"Libe","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"2024031914013579500_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nm.4474","article-title":"A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment","volume":"24","author":"Hyer","year":"2018","journal-title":"Nat Med"},{"key":"2024031914013579500_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41375-018-0167-0","article-title":"Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia","volume":"33","author":"Barghout","year":"2019","journal-title":"Leukemia"},{"key":"2024031914013579500_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/bloodadvances.2018026880","article-title":"Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells","volume":"3","author":"Best","year":"2019","journal-title":"Blood Adv"},{"key":"2024031914013579500_bib20","doi-asserted-by":"crossref","first-page":"100834","DOI":"10.1016\/j.tranon.2020.100834","article-title":"UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer","volume":"13","author":"Liu","year":"2020","journal-title":"Transl Oncol"},{"key":"2024031914013579500_bib21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-21-0344","article-title":"Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small-cell lung cancer","volume":"28","author":"Majeed","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024031914013579500_bib22","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","article-title":"Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma","volume":"133","author":"Zhuang","year":"2019","journal-title":"Blood"},{"key":"2024031914013579500_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41420-022-00950-5","article-title":"GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discov"},{"key":"2024031914013579500_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"2024031914013579500_bib25","doi-asserted-by":"crossref","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024031914013579500_bib26","article-title":"Authentication of human and mouse cell lines by short tandem repeat (STR) DNA genotype analysis","volume-title":"Assay guidance manual","author":"Almeida","year":"2004"},{"key":"2024031914013579500_bib27","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024031914013579500_bib28","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1021\/acschembio.0c00343","article-title":"High-throughput screening to identify inhibitors of the type I interferon-major histocompatibility complex class I pathway in skeletal muscle","volume":"15","author":"Kinder","year":"2020","journal-title":"ACS Chem Biol"},{"key":"2024031914013579500_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.31083\/j.fbl2701005","article-title":"ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1","volume":"27","author":"Wu","year":"2022","journal-title":"Front Biosci"},{"key":"2024031914013579500_bib30","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-20-2694","article-title":"SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243","volume":"81","author":"Murai","year":"2021","journal-title":"Cancer Res"},{"key":"2024031914013579500_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-019-0832-4","article-title":"Emerging organoid models: leaping forward in cancer research","volume":"12","author":"Fan","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2024031914013579500_bib32","first-page":"97","article-title":"Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method","volume":"6","author":"Zhang","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2024031914013579500_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/07435809809032699","article-title":"Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors","volume":"24","author":"Arola","year":"1998","journal-title":"Endocr Res"},{"key":"2024031914013579500_bib34","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3390\/diagnostics11122172","article-title":"INSM1, a novel biomarker for detection of neuroendocrine neoplasms: cytopathologists' view","volume":"11","author":"Maleki","year":"2021","journal-title":"Diagnostics"},{"key":"2024031914013579500_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1479-5876-10-198","article-title":"Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening","volume":"10","author":"Nilubol","year":"2012","journal-title":"J Transl Med"},{"key":"2024031914013579500_bib36","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-15-2256","article-title":"Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma","volume":"22","author":"Satoh","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024031914013579500_bib37","first-page":"691","article-title":"New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex","volume":"51","author":"Leibovitz","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"2024031914013579500_bib38","doi-asserted-by":"crossref","first-page":"33030","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"key":"2024031914013579500_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13046-022-02464-5","article-title":"Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer","volume":"41","author":"Laha","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2024031914013579500_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2024031914013579500_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","article-title":"IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer","volume":"64","author":"De Martino","year":"2019","journal-title":"Endocrine"},{"key":"2024031914013579500_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/ERC-11-0270","article-title":"The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells","volume":"19","author":"De Martino","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2024031914013579500_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/ERC-18-0500","article-title":"MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer","volume":"26","author":"Creemers","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2024031914013579500_bib44","doi-asserted-by":"crossref","first-page":"103173","DOI":"10.1016\/j.isci.2021.103173","article-title":"Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway","volume":"24","author":"Murai","year":"2021","journal-title":"iScience"},{"key":"2024031914013579500_bib45","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.3390\/cancers13184601","article-title":"Precision oncology with drugs targeting the replication stress, ATR, and schlafen 11","volume":"13","author":"Jo","year":"2021","journal-title":"Cancers"},{"key":"2024031914013579500_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.surg.2022.09.027","article-title":"Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications","volume":"173","author":"Baregamian","year":"2023","journal-title":"Surgery"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0085\/3422251\/crc-24-0085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/3\/834\/3430387\/crc-24-0085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/3\/834\/3430387\/crc-24-0085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T10:03:41Z","timestamp":1710842621000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/3\/834\/741849\/Activity-of-the-Ubiquitin-activating-Enzyme"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,19]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0085","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25436370.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436364.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436373.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436382","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436370","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436358.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436355.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436364","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436352","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436355","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436379","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436352.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436367","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436382.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436391.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436397.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436394.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436388.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436385.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436391","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436373","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436361","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436397","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436385","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436388","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436376","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436400.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436379.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436358","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436376.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436361.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25436367.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7128618.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7128618","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}